Baxter International (BAX) : The money flow is calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades, which was negative (1.06 million) in Baxter International (BAX). On Wednesday, The value of composite uptick trades was $0.96 million, whereas, the value of composite downtick trades was $2.02 million and the ratio between the two was 0.47, indicating selling on strength. Traders involved in block trades booked profits in their holdings as seen in the transactions on downticks valued at $1.04 million. The negative money flow of ($1.04 million) shows selling on strength. Baxter International (BAX) gained $0.51 intraday at $46.71 and registrered 1.1% for the week.
Also, Evercore ISI Group initiates coverage on Baxter International (NYSE:BAX) The shares have been rated Buy. The rating by the firm was issued on May 4, 2016.
Baxter International (NYSE:BAX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $46.48 and $46.46 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $46.86. The buying momentum continued till the end and the stock did not give up its gains. It closed at $46.70, notching a gain of 1.08% for the day. The total traded volume was 1,663,151 . The stock had closed at $46.20 on the previous day.
The stock has recorded a 20-day Moving Average of 2.45% and the 50-Day Moving Average is 4.35%. In a related news, Almeida Jose E, CEO of Baxter International Inc had purchased 11,691 shares on May 23, 2016 in a transaction. The price per share was $42.75 and the total amount of the disclosed transaction was $499,790.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.